Shanghai Pharmaceuticals Holding Co.

Shanghai, China

Shanghai Pharmaceuticals Holding Co.

Shanghai, China
SEARCH FILTERS
Time filter
Source Type

— The Global Saffron Market Research Report 2017is a professional and in-depth study on the current state of the Saffron industry. In a word, This report studies Saffron in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with capacity, production, price, revenue and market share for each manufacturer. Key companies included in this research are Novin Saffron, Shahri Saffron, Rowhani Saffron, Tarvand, Azafranes Manchegos, S.L, Krokos-Kozani and Shanghai Pharmaceuticals Holding Co.. Market Segment by Region, this report splits Global into several key Region, with sales, revenue, market share and growth rate of Saffron in these regions, from 2011 to 2022 (forecast), like North America, Europe, China, Japan, Southeast Asia and India. Firstly, Saffron Market On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Thread Form, Powder Form and Liquid Form. On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales) , market share and growth rate of Saffron for each application, including Retail, Food Service (Restaurants, Hotels etc), Medical & Pharmaceuticals, Cosmetics (Skin Care, Hair Care) and Others. 7 Global Saffron Manufacturers Profiles/Analysis 7.1 Novin Saffron 7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.1.2 Saffron Product Category, Application and Specification 7.1.2.1 Product A 7.1.2.2 Product B 7.1.3 Novin Saffron Saffron Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.1.4 Main Business/Business Overview 7.2 Shahri Saffron 7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.2.2 Saffron Product Category, Application and Specification 7.2.2.1 Product A 7.2.2.2 Product B 7.2.3 Shahri Saffron Saffron Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.2.4 Main Business/Business Overview 7.3 Rowhani Saffron 7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors 7.3.2 Saffron Product Category, Application and Specification 7.3.2.1 Product A 7.3.2.2 Product B 7.3.3 Rowhani Saffron Saffron Capacity, Production, Revenue, Price and Gross Margin (2012-2017) 7.3.4 Main Business/Business Overview Figure Picture of Saffron Figure Global Saffron Production (MT) and CAGR (%) Comparison by Types (Product Category) (2012-2022) Figure Global Saffron Production Market Share by Types (Product Category) in 2016 Figure Product Picture of Thread Form Table Major Manufacturers of Thread Form Figure Product Picture of Powder Form Table Major Manufacturers of Powder Form Figure Product Picture of Liquid Form Table Major Manufacturers of Liquid Form Figure Global Saffron Consumption (MT) by Applications (2012-2022) Figure Global Saffron Consumption Market Share by Applications in 2016 Figure Retail Examples Figure Food Service (Restaurants, Hotels etc) Examples Figure Medical & Pharmaceuticals Examples Figure Cosmetics (Skin Care, Hair Care) Examples Figure Others Examples Figure Global Saffron Market Size (Million USD) , Comparison (MT) and CAGR (%) by Regions (2012-2022) Figure North America Saffron Revenue (Million USD) and Growth Rate (2012-2022) Figure Europe Saffron Revenue (Million USD) and Growth Rate (2012-2022) Figure China Saffron Revenue (Million USD) and Growth Rate (2012-2022) Figure Japan Saffron Revenue (Million USD) and Growth Rate (2012-2022) Figure Southeast Asia Saffron Revenue (Million USD) and Growth Rate (2012-2022) Figure India Saffron Revenue (Million USD) and Growth Rate (2012-2022) Figure Global Saffron Revenue (Million USD) Status and Outlook (2012-2022) Figure Global Saffron Capacity, Production (MT) Status and Outlook (2012-2022) Figure Global Saffron Major Players Product Capacity (MT) (2012-2017) Table Global Saffron Capacity (MT) of Key Manufacturers (2012-2017) Table Global Saffron Capacity Market Share of Key Manufacturers (2012-2017) Figure Global Saffron Capacity (MT) of Key Manufacturers in 2016 Figure Global Saffron Capacity (MT) of Key Manufacturers in 2017 Figure Global Saffron Major Players Product Production (MT) (2012-2017) Table Global Saffron Production (MT) of Key Manufacturers (2012-2017) Table Global Saffron Production Share by Manufacturers (2012-2017) Figure 2016 Saffron Production Share by Manufacturers Figure 2017 Saffron Production Share by Manufacturers Figure Global Saffron Major Players Product Revenue (Million USD) (2012-2017) For more information, please visit http://www.reportsweb.com/global-saffron-market-research-report-2017


News Article | April 28, 2017
Site: www.acnnewswire.com

Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical products and service markets, released its first quarterly report of 2017 on the night of 27 April, 2017. Data showed that During the Reporting Period, Shanghai Pharmaceuticals recorded operation revenue of RMB33.129 billion (Unit: RMB, following the same), representing an increase of 13.16% on a YOY basis. Net profit attributable to the equity holders of the listed company was RMB0.999 billion, representing a YOY increase of 12.37%. Net profit attributable to the equity holders of the listed company after deduction of non-recurring profit or loss was RMB0.939 billion, representing a YOY increase of 20.82%, achieved earnings per share RMB0.3717, earnings per share after deduction of non-recurring profit or loss was RMB0.3491. During the Reporting Period, the Company's net cash flow from operating activities was RMB0.376 billion, representing a YOY increase of 14.81%, fulfilling the budget target for the first quarter of 2017. In respect of pharmaceutical manufacturing business, Shanghai Pharmaceuticals achieved operating revenue of RMB3.794 billion in the first quarter of 2017, representing a YOY increase of 19.94% and a gross profit margin of 50.61%, representing a decrease of 0.34 percentage point as compared with the corresponding period of last year. The operating profit margin after deducting the costs was 14.14%, representing a YOY increase of 1.33 percentage points. In particular, sales revenue generated from its 60 key products increased by 15.07% on a YOY basis to RMB1.893 billion, accounting for 49.90% of the manufacturing sales. Average gross profit margin of key products was 69.82%, representing a YOY increase of 1.81 percentage points. Among the key products, there are 26 categories were expected to record sales revenue of more than RMB100 million over the year. In respect of pharmaceutical service, the Company achieved operating revenue of RMB29.485 billion in its pharmaceutical distribution business, representing a YOY increase of 12.93% and a gross profit margin of 6.15%, representing an increase of 0.16 percentage point as compared with the corresponding period of last year. The operating profit margin after deducting the costs of sales and administration was 2.64%, representing a YOY increase of 0.02 percentage point. During the Reporting Period, the operating revenue from the pharmaceutical retail business amounted to RMB1.280 billion, representing a YOY increase of 4.30% and a gross profit margin of 15.88%, representing a YOY increase of 0.34 percentage point. The operating profit margin after deducting the costs of sales and administration was 0.26%, representing a YOY decrease of 1.1 percentage points. The implementation of "two-invoice" policy will benefice large pharmaceutical distribution enterprises in expanding market share in the next three to five years. The Company's direct sales proportion in those provinces is thus expected to further enhance, which, in the long term, will strengthen the Company's profitability in distribution business. During the Reporting Period, Shanghai Pharmaceuticals Co., Ltd., the subsidiary of the Company, basically completed the layout of market in North Jiangsu through merger and acquisition of Xuzhou Pharmaceutical Co., Ltd. and Xuzhou Huaihai Pharmaceutical Co., Ltd.. The Company continued to manage the stock equity and enhance its competitiveness in Guangdong region through acquiring 31.593% equity of Guangzhou Z.S.Y Pharmaceutical Co., Ltd held by Guangzhou Zhongda Industry Group Co., Ltd Shanghai Pharmaceuticals also remarks that, as the integrated industrial company in the PRC that has leading positions in pharmaceutical manufacturing and business, the Company will ride on the industry reforms and actively grasp the industry trends to accelerate its transformation and development, and put more efforts in M&A activities, so as to maintain its leading status in the industry. Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS


Patent
Mitsubishi Group and Shanghai Pharmaceuticals Holding Co. | Date: 2014-01-22

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]:^(1) is a cycloalkyl group and the like, R^(22) is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is -O- and the like, and R^(3) to R^(6) are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.


Patent
Shanghai Pharmaceuticals Holding CO. and Mitsubishi Group | Date: 2013-09-13

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor. wherein R^(1 )is a cycloalkyl group or an alkyl,R^(22 )is an optionally substituted aryl and the like,R is a lower alkyl group,R^(3), R^(4), R^(5 )and R^(6 )are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl,or a pharmaceutically acceptable salt thereof.


Patent
Shanghai Pharmaceuticals Holding Co. and Mitsubishi Group | Date: 2012-03-15

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R^(1 )is a cycloalkyl group and the like, R^(22 )is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is O and the like, and R^(3 )to R^(6 )are the same or different and a hydrogen atom and the like;or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.


Patent
Mitsubishi Group and Shanghai Pharmaceuticals Holding Co. | Date: 2016-01-12

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R^(1 )is a cycloalkyl group and the like, R^(22 )is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is O and the like, and R^(3 )to R^(6 )are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.


Patent
Mitsubishi Group and Shanghai Pharmaceuticals Holding Co. | Date: 2015-10-21

The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I] which is useful as a renin inhibitor.^(1) is a cycloalkyl group or an alkyl,R^(22) is an optionally substituted aryl and the like,R is a lower alkyl group,R^(3), R^(4), R^(5) and R^(6) are the same or different, and are a hydrogen atom, an optionally substituted carbamoyl, an optionally substituted alkyl, or alkoxycarbonyl,or a pharmaceutically acceptable salt thereof.


Patent
Changzhou Pharmaceutical Factory and Shanghai Pharmaceuticals Holding Co. | Date: 2013-06-21

The present invention relates to a compound solid preparation and the preparation method therefor and specifically relates to a valsartan-amlodipine compound solid preparation and the preparation method therefor. The valsartan-amlodipine compound solid preparation comprises valsartan particles and an amlodipine premix. The valsartan particles are prepared by preparing wet valsartan particles from a mixture obtained by mixing valsartan and a pharmaceutic adjuvant with an ethanol aqueous solution as a wetting agent and drying the wet valsartan particles. The amlodipine premix is prepared by mixing amlodipine and a pharmaceutic adjuvant. The valsartan-amlodipine compound solid preparation according to the present invention and the preparation method thereof can prevent the two main ingredients, amlodipine and valsartan, from interfering each other, and the preparation method is relatively simple and suitable for large-scale industrial production.


Patent
Zhejiang University and Shanghai Pharmaceuticals Holding Co. | Date: 2012-07-27

Disclosed are as represented by Formula (I) a quinazoline derivative and a pharmaceutical acceptable salt thereof, or, an enantiomer, a non-enantiomer, a tautomer, a racemate, a solvate, a metabolic precursor, or a prodrug of both. Also disclosed are a preparation method therefor, an intermediate, a pharmaceutical composition having the quinazoline derivative, and an application thereof. The quinazoline derivative of the present invention is provided with improved anti-tumor activity.


News Article | October 31, 2016
Site: www.businesswire.com

LONDON--(BUSINESS WIRE)--Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq:HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited (“SHPL”), its 50:50 Prescription Drug joint venture with a subsidiary of Shanghai Pharmaceuticals Holding Co., Limited (“Shanghai Pharma”), has today received US$59.5 million from the Shanghai government under the terms of their December 2015 land compensation agreement (the “Compensation Agreement”). As announced on December 9, 2015, SHPL and th

Loading Shanghai Pharmaceuticals Holding Co. collaborators
Loading Shanghai Pharmaceuticals Holding Co. collaborators